Intracranial delivery of the IL13Rα2-targeted CAR-T was well-tolerated, induced transient anti-glioma responses, and increased tumor necrotic volume (55). A case report indicated intracranial infusion of IL13Rα2-targeted CAR-T was associated with no toxic effects of grade 3 or higher. This evidence concerns the gene IL13RA2 and central nervous system cancer.